Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A plus lenvatinib in first-line advanced hepatocellular carcinoma
2023-505698-34-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of quavonlimab + pembrolizumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events and 5 more. Started Jul 2023; status: completed.
02
Drugs
quavonlimab + pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-505698-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505698-34-00.